DJIA 17,131.86 47.37 0.28%
NASDAQ 4,838.64 8.17 0.17%
S&P 500 2,017.46 2.57 0.13%
market minute promo

Vertex Pharmaceuticals (NASDAQ: VRTX)

113.25 3.25 (2.95%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

VRTX $113.25 2.95%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $110.64
Previous Close $110.00
Daily Range $109.08 - $114.25
52-Week Range $96.43 - $143.45
Market Cap $27.7B
P/E Ratio -35.83
Dividend (Yield) $0.00 (0.0%)
Volume 1,858,636
Average Daily Volume 2,290,748
Current FY EPS -$2.65




Drug Makers

Vertex Pharmaceuticals (VRTX) Description

The Company is in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. Website:

News & Commentary Rss Feed

3 Large-Cap Biotech Stocks Whose Valuations Should Make You Skeptical

Bigger is not always better! All three of these biotech stocks boast $20 billion-plus valuations, and all may be significantly overpriced.

Vertex (VRTX) Provides Updates on Cystic Fibrosis Pipeline

Vertex's Kalydeco Gets Priority Review for Expanded Use

Vertex to Test New Cystic Fibrosis Drugs, Seeking Broader, More Effective Treatments

Nasdaq 100 Movers: ILMN, VIAB

Morgan Stanley Says These 9 Health Care Stocks Are Best-Positioned, Despite Rising Drug Prices

A Double-Dose of Bad News Rocks Vertex Pharmaceuticals in September

Usually a positive catalyst, Vertex Pharmaceuticals' cystic fibrosis drugs wind up as its undoing in September.

Benzinga's Top Upgrades

Morgan Stanley On Big Biotech: Upgrades, Pfizer, Vertex, Alexion, Cuts Gilead, Valeant

The Zacks Analyst Blog Highlights: Regeneron, Vertex, Gilead, Biogen and Celgene

See More VRTX News...

VRTX's Top Competitors

VRTX $113.25 (2.95%)
Current stock: VRTX
AMGN $153.04 (2.31%)
Current stock: AMGN
GILD $99.50 (-1.14%)
Current stock: GILD
BIIB $264.67 (-1.67%)
Current stock: BIIB